A federal jury in Delaware found that Revance's rival product infringed patents for Allergan's market-leading neurotoxin ...

AbbVie and its subsidiary Allergan have had a long run of unchallenged success in the market with cosmetic and therapeutic ...

A federal jury July 18 said Revance Therapeutics' skin medication infringed on patents for anti-wrinkle treatment Botox and owes AbbVie-owned Allergan $56 million.

A Delaware federal jury said on Friday that Revance Therapeutics owes AbbVie's Allergan Inc $56 million after finding that ...

About Revance Revance is a biotechnology company setting the new standard in healthcare with innovative aesthetic and therapeutic offerings that enhance patient outcomes and physician experiences.

Revance stockholders must tender by FEBRUARY 4 DEADLINE for transaction to close Crown's tender offer will expire at one minute past 11:59 p.m. Eastern Time, on February 4, 2025.

Revance (RVNC) announced that privately held Crown Laboratories has commenced a cash tender offer to acquire all outstanding shares of common stock of Revance at a price of $3.10 per share in cash ...

Crown Laboratories and Revance (RVNC) announced that they have amended and restated the merger agreement entered into by the parties on August 11, pursuant to which the companies will seek to ...

(Reuters) -Crown Laboratories would buy the anti-wrinkle injection maker Revance Therapeutics at a roughly 50% lower price compared to an original agreement signed in August, the companies said on ...

Revance Therapeutics' lead product, Daxxify (daxibotulinumtoxinA-Ianm) injection, is indicated to treat frown lines. Following the merger, Revance will be wholly owned by Crown, and its stock will ...

Revance Therapeutics (NASDAQ:RVNC) stock is on the rise Monday after the biotechnology company announced a merger agreement with private skincare company Crown Laboratories. Crown Laboratories ...